Literature DB >> 12788794

Deferiprone and hepatic fibrosis.

Gary M Brittenham, David G Nathan, Nancy F Olivieri, John B Porter, Martin Pippard, Elliott P Vichinsky, David J Weatherall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12788794     DOI： 10.1182/blood-2002-10-3173

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Thalassaemia major: the murky story of deferiprone.

Authors:  Julian Savulescu
Journal:  BMJ       Date:  2004-02-14

Review 2.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

Review 3.  Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases.

Authors:  Catherine M Cahill; Debomoy K Lahiri; Xudong Huang; Jack T Rogers
Journal:  Biochim Biophys Acta       Date:  2008-12-29

Review 4.  Al-hijamah and oral honey for treating thalassemia, conditions of iron overload, and hyperferremia: toward improving the therapeutic outcomes.

Authors:  Salah Mohamed El Sayed; Hussam Baghdadi; Ashraf Abou-Taleb; Hany Salah Mahmoud; Reham A Maria; Nagwa S Ahmed; Manal Mohamed Helmy Nabo
Journal:  J Blood Med       Date:  2014-10-30

5.  Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

Authors:  Nancy F Olivieri; Amir Sabouhanian; Brenda L Gallie
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.